Summary
Updated Aug 30, 2026
Richard A. Barasch is Director of Starling Oncology, Inc. (STLN). 4 SEC Form 4 filings on record going back to 2024, most recently on 12 August 2025.
Recent Transactions
4Every recent SEC Form 4 transaction Richard A. Barasch has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Richard A. Barasch files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- M33 Growth I L.P. - $20.70M of STLN open-market activity in the last 12 months
- Jorey Chernett - $2.69M of STLN open-market activity in the last 12 months
- Brad Hively - $2.00M of STLN open-market activity in the last 12 months
- Mohit Kaushal - $335K of STLN open-market activity in the last 12 months
- Yale Podnos - $276K of STLN open-market activity in the last 12 months
- Mark L. Pacala - $200K of STLN open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Richard A. Barasch?
Richard A. Barasch is a corporate insider, tracked as Director of Starling Oncology, Inc. (STLN). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Richard A. Barasch last file a Form 4?
The most recent primary Form 4 on record is dated 12 August 2025, one of 4 filings going back to 2024.
Where can I see all of Richard A. Barasch's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Richard A. Barasch and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
